Home Research Staff


Prof. Dr. Gerhard Gründer

Phone: +49 621 1703-1900

Fax: +49 621 1703-80-1900


Main Medical Building, Groundfloor, Room 056



Hanna Böhm 
Personal Assistant

Phone: +49 621 1703-1901
Fax: +49 621 1703-801901


Main Medical Building, Groundfloor, Room 037


Publications in peer reviewed journals since 2006

TOP 5 publications:

  1. Reimold M, Batra A, Knobel A, Smolka MN, Zimmer-Butz A, Mann K, Solbach C, Reischl G, Schwärzler F, Gründer G, Machulla HJ, Bares R, Heinz A. Anxiety is associated with reduced central serotonin transporter availability in unmedicated patients with unipolar major depression: a [11C]DASB PET study. Mol Psychiatry. 2008 13(6):606-13, 557.
  2. Gründer G, Cumming P. The downside of downregulation. Brain. 2019 142(6):1500-1502.
  3. Quednow BB, Brinkmeyer J, Mobascher A, Nothnagel M, Musso F, Gründer G, Savary N, Petrovsky N, Frommann I, Lennertz L, Spreckelmeyer KN, Wienker TF, Dahmen N, Thuerauf N, Clepce M, Kiefer F, Majic T, Mössner R, Maier W, Gallinat J, Díaz-Lacava A, Toliat MR, Thiele H, Nürnberg P, Wagner M, Winterer G. Schizophrenia risk polymorphisms in the TCF4 gene interact with smoking in the modulation of auditory sensory gating. Proc Natl Acad Sci U S A. 2012 109(16):6271-6. Epub 2012 Mar 26.
  4. Hansson AC, Gründer G, Hirth N, Noori HR, Spanagel R, Sommer WH. Dopamine and opioid systems adaptation in alcoholism revisited: Convergent evidence from positron emission tomography and postmortem studies. Neurosci Biobehav Rev. 2019 106:141-164. Epub 2018 Sep 19.
  5. Brown D, Nakagome K, Cordes J, Brenner R, Gründer G, Keefe RSE, Riesenberg R, Walling DP, Daniels K, Wang L, McGinniss J, Sand M. Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. Schizophr Bull. 2019 45(2):350-359. Epub 2018 May 1.

Zentralinstitut für Seelische Gesundheit (ZI) - https://www.zi-mannheim.de